Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants

9 Feb 2022

Abstract excerpt

Abstract The wide transmission and host adaptation of SARS-CoV-2 have led to the rapid accumulation of mutations, posing significant challenges to the effectiveness of vaccines and therapeutic antibodies. Although several neutralizing antibodies were authorized for emergency clinical use, convalescent patients derived natural antibodies are vulnerable to SARS-CoV-2 Spike mutation. Here, we describe the screen of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35140196
DOI: 10.1038/s41392-022-00912-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsPMID 35140196Read ↗

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read ↗

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralizationSemantic proximity Read ↗

Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster modelsSemantic proximity Read ↗

Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1Semantic proximity Read ↗

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2Semantic proximity Read ↗

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including OmicronSemantic proximity Read ↗

Ultrapotent SARS-CoV-2 neutralizing antibodies effectively block new-emerging mutational variantsSemantic proximity Read ↗

Development of an Escape-resistant SARS CoV-2 Neutralizing Synthetic NanobodySemantic proximity Read ↗

Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2Semantic proximity Read ↗

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of ConcernSemantic proximity Read ↗

Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.Semantic proximity Read ↗

Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 VariantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.